Core Insights - Nucleic acid drugs represent a third-generation drug model that enables precise disease treatment by regulating gene expression or intervening in protein synthesis, offering advantages such as targeting undruggable targets, long-lasting effects, and shorter development cycles [1][4] - The global nucleic acid drug market is projected to exceed $23 billion in 2024 and surpass $50 billion by 2030, with small nucleic acid drugs being the core segment, increasing from $2.9 billion in 2020 to $5.1 billion in 2024 [1][8] - China is rapidly advancing in the nucleic acid drug sector, supported by comprehensive policies and nearly 200 companies accelerating their development, with several products entering clinical trials and expected to launch in the next three years [1][4][10] Industry Overview - Nucleic acid drugs are therapeutic molecules based on nucleic acids (DNA or RNA) that treat diseases by directly regulating gene expression or intervening in protein synthesis [2][3] - The industry is characterized by high technical barriers and strong reliance on imported raw materials and production equipment [4] Market Dynamics - The global nucleic acid drug market is experiencing significant growth due to an aging population and rising chronic disease rates, with a compound annual growth rate (CAGR) exceeding 15% from 2023 to 2030 [6][8] - Over 900 companies are involved in nucleic acid drug development globally, with a total of 2,600 projects, of which 13.76% are for rare diseases [6][8] Competitive Landscape - The competitive landscape in China's nucleic acid drug industry is characterized by three tiers: leading companies like Wobang Pharmaceutical and Rebio Biotech, traditional pharmaceutical companies like Hengrui Medicine, and startups focusing on mRNA vaccines and new delivery technologies [10][11] - The first tier companies are gaining global market influence through technology licensing and innovative delivery systems [10][11] Future Trends - The nucleic acid drug industry in China is expected to evolve through international innovation and capital empowerment, with a focus on liver-targeted delivery and AI-assisted design [12][13] - The market is anticipated to shift from rare diseases to common diseases, with significant growth in areas such as cardiovascular and metabolic diseases, driven by advancements in production capabilities and reimbursement systems [13][14]